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sponding to the fastest leg run 0.4 m/s slower. The bilateral coordina-
tion of gait was assessed by the Phase Coordination Index (PCI).
Results: During tied condition, the step lengths of the slowest and
fastest leg were respectively 26.563.0 and 34.963.9 cm (p5ns) with
a fastest/slowest ratio of 1.360.5. During the BSR condition these
values resulted respectively 31.164.9 cm, 29.964.0 cm (p5ns) and
1.160.8 (p50.03 vs. tied), thus revealing a more symmetric gait as
compared to the tied condition. During WSR, these values were
respectively 22.562.5 cm, 41.062.8 cm (p50.0003) e 1.860.2
(P50.002 vs tied), thus revealing a more asymmetric gait. However,
when examining the bilateral coordination of the lower limbs, gait
was significantly more coordinated during WSR than during tied
(p50.05) or BSR (p50.02): the PCI values were 39.8610.3,
47.3610.7, and 52.3611.5, respectively. As a consequence the
global performance of gait resulted improved during the WSR as
compared to the tied condition: stride length increased from
61.065.0 to 64.165.9 cm (p50.05) whereas cadence decreased from
147617 to 11869 steps/min (p50.04).
Conclusions: Our findings reveal that during normal gait (tied) the
locomotor system reduces the step length of the less affected side in
order to preserve the symmetry between legs. In fact, during the
WSR condition, in spite of the increased asymmetry, gait improves
in terms of stride length and coordination.
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Gait analysis using a wearable accelerometer system:
Comparison between control subjects and patients with
Parkinson’s disease
D. Maquet, J.-L. Croisier, F. Robert, S. LeScanf,
C. Rodriguez de la Cruz, T. Bury, G. Garraux (Liege, Belgium)
Objective: To examine specific gait parameters using a wearable
accelerometer system in PD patients as compared with normal
individuals.
Background: Walking is one of the most universal human activ-
ities and disorders of gait are one of the most cumbersome symptoms
in Parkinson’s disease (PD). Quantitative gait analysis using external
devices is particularly relevant to detect and characterize walking dis-
orders, particularly in patients with neurological diseases.
Methods: Ten PD patients (mean age: 6369 years and body mass
index: 2363 kg/m2) and 10 control subjects (mean age: 6469 years
and body mass index: 2462 kg/m2) were included in the study. PD
patients were studied on medication. Mean disease duration was 8
years and mean score on Hoehn & Yahr scale was 2 Participants
were asked to walk at their comfortable speed under standardized ex-
perimental conditions in a 40 m-long hospital corridor. The gait anal-
ysis system used in this study (LocometrixTM) included an accelera-
tion sensor, a recording device and a software for signal processing.
The sensor was composed of two accelerometers placed perpendicu-
larly and was incorporated into a semi-elastic belt placed over the
L3-L4 intervertebral space. We extracted the following gait parame-
ters during a 20-second period of stabilized walking: stride fre-
quency, stride length, stride regularity (similarity of cranio-caudal
movements over successive strides) and step symmetry (similarity of
left and right cranio-caudal movements). Walking speed was also
measured.
Results: Walking speed and stride length were significantly lower
in PD patients in comparison with healthy controls (Table 1). Stride
regularity and step symmetry were also altered in the PD group but
this difference did not reach statistical significance.
Conclusions: Although this study is limited by a small sample
size, our preliminary results showed that quantitative gait parameters
can be easily studied in PD patients using a wearable accelerometer
system. This approach still needs to be validated in PD but opens
interesting perspectives to track modifications of quantitative gait pa-
rameters associated with disease progression and to evaluate more
accurately the effects of specific therapeutic interventions.
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Ambulatory monitoring of energy expenditure and physical
activity levels using the SenseWear ArmbandTM system in
Parkinson’s disease
C. Rodriguez de la Cruz, T. Bury, S. Le Scanff, F. Robert, D.
Maquet, J.-L. Croisier, G. Garraux (Liege, Belgium)
Objective: To monitor physical activity levels and energy expend-
iture in daily life using the ambulatory SenseWear ArmbandTM sys-
tem in Parkinson’s disease (PD) patients and control subjects.
Background: One goal of therapeutic interventions in PD is to
improve the level of mobility and physical activity during daily life
but these important outcomes remain difficult to quantify with a high
accuracy.
Methods: We recruited 11 PD patients (mean age: 63.3367.81
years and B.M.I.: 25.163.24 kg/m2) and 11 control subjects (mean
TABLE 1 (525).
Gait parameters Controls PD p value
Walking speed (m/s) 1.39 6 0.19 1.16 6 0.3 0.05
Stride frequency (Hz) 0.92 6 0.04 0.92 6 0.1 NS
Stride length (m) 1.51 6 0.18 1.26 6 0.26 0.02
Stride regularity (au) 270 6 47 239 6 67 NS
Step symmetry (au) 214 6 52 185 6 79 NS
m5meters; s5seconds; au 5arbitrary unit; NS5not significant.
FIG. 1 (524).
TABLE 1 (526). Parameters derived from 24h ambulatory SenseWear
ArmbandTM recordings
Controls PD P value
TEE 2286 6 563 23366584 NS
0-1 MET
EE (cal) 6876166 8946224 NS
Time (min) 6586163 7686179 NS
1-2 MET
EE (cal) 3926119 5606176 NS
Time (min) 4086163 4246211 NS
2-3 MET
EE (cal) 5626155 3616121 0.002
Time (min) 222674 147655 0.01
3-6 MET
EE (cal) 6286557 5066442 NS
Time (min) 1506103 100680 NS
>6MET
EE (cal) 17620 1264 NS
Time (min) 2.262.4 667 NS
Number of steps 756363194 527961820 0.045
TEE5total energy expenditure (EE); cal5calories; min5minutes.
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age: 63.3462.6 years and B.M.I.: 22.5462.77 kg/m2). PD patients
were studied on medication. Mean disease duration was 9.2 years
and mean score on Hoehn & Yahr scale was 1.9. The SenseWear
ArmbandTM system was placed on the right upper arm during 24
hours on a week-end day. The system includes a two-axis accelerom-
eter, a galvanic skin response sensor, a heat flux sensor, a skin tem-
perature sensor and at least a near-body ambient temperature sensor.
We recorded the total energy expenditure (T.E.E.), and both energy
expenditure (E.E.) and time (T.) at 0-1, 1-2, 2-3, 3-6 & >6 metabolic
equivalents (MET53.5 mlO2.Kg-1.min-1) as well as the total num-
ber of steps. On a separate day, PD patients also performed a trian-
gular aerobic test at 10 watts/min on a cyclo-ergometer to estimate
their VO2max and maximal heart rate (MHR).
Results: Despite PD patients were on medication, E.E. & T. at 2-3
METs and steps number were significantly lower than in healthy con-
trols (Table 1).
Mean group VO2max and MHR were 25 ml/kg/min and 125/min,
respectively. There was no significant linear correlation between
VO2max and T.E.E. or between VO2max and steps number in the
PD group.
Conclusions: Although this study is limited by a small sample
size, our results showed that energy expenditure and physical activity
levels can be easily monitored during everyday life using the ambu-
latory SenseWear ArmbandTM system. This device still needs to be
fully validated in PD but it opens interesting perspectives to monitor
sustained motor effects after therapeutic interventions including a
physical reconditioning program. In this case, the aerobic triangular
test may also be indicated for longitudinal follow up.
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Nine-hundred patients with Parkinson’s disease: A twenty-year
experience in a public hospital
N.S. Garretto, T. Arakaki, J.A. Bueri, V.E. Diaz Aragunde,
V.A. Pujol Lereis, N.E. Campora, M.R. Arce (Caba,
Buenos Aires, Argentina)
Objective: To analyze the clinical features and treatment trends of
PD patients treated in our Movement Disorder Clinic in the last
twenty years.
Background: There are guidelines for the treatment of the early
stages of PD. However, for many patients levodopa is still a choice
as an initial treatment.
Methods: We performed a retrospective study of 3,590 medical
records from the period 1988-2008. We selected 900 patients with
idiopathic PD (25%). We analyzed age, gender, family history, stage
of the disease, features of the progression of the disease, and
treatments.
Results: Demographic data: Age at onset: 57.9610.6 years
(51.8% men). Family History of PD:10%. Clinical features at first
visit: duration of disease: 48 months[1-360], previous diagnosis of
PD: 88,3% (in 70% of patients, diagnosis was made immediately
when symptoms began); motor fluctuations: 39.9%, dyskinesia:
29.2%, Hoehn&Yahr stage I: 24.1%, II: 63.3%, III: 11.4%, IV: 0.9%,
V:0.3%. Progression during follow-up (FU): dyskinesia: 42.1% (FU:
72 months [4-252]), motor fluctuations: 54.3 % (FU: 60 months [2-
252]), cognitive impairment:13.1% (FU: 108 months [24-336]), hallu-
cinations: 16% (FU: 120 months [24-336]), depression: 31.4% (FU:
54 months [1-360]). Initial treatment with levodopa 1988-1997: 85%;
1998-2008: 79%; in patients aged<65 years: 83.7% and 75.8%,
respectively.
Conclusions: The demographic and clinical features in our patient
population are coincident with those in the literature. The large num-
ber of patients with a prior diagnosis of PD is accounted for by the
fact that ours is a referral center. Levodopa remained the first choice
for initial therapy in most patients, in spite of the availability of
more optional drugs in the last decade and the recommendations for
early disease treatment. We suspect that economical factors are an
important determinant in the choice of the initial therapy, although
limited knowledge of other alternatives by non-experts could be the
cause in some cases.
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Dyskinesia-hyperpyrexia syndrome: Another Parkinson’s disease
emergency
S. Gil, A. Contreras, R. Fernandez, F. Grandas (Madrid, Spain)
Objective: To present a case of dyskinesia-hyperpyrexia in a
patient with Parkinson’s disease (PD), a new PD emergency different
from the parkinsonism-hyperpyrexia syndrome (PHS).
Background: PHS is a rare though life-threatening PD complica-
tion. It is characterized by hyperthermia, autonomic dysfunction, con-
sciousness disturbances, rigidity and elevated serum creatinekinase
(CK). No PD patients with a dyskinetic status- instead of severe
rigidity- associated with hyperthermia, rhabdomyolisis and a
confusional state have been previously described.
Methods: A 68-year-old female, with a twelve-year history of PD
complicated with motor fluctuations and dyskinesias, was treated
with levodopa/carbidopa/entacapone, pramipexole and amantadine.
She experienced transient visual hallucinations that became more fre-
quent over the last six months. Two days before her admission severe
continuous generalized dyskinesias appeared followed by confusion,
drowsiness and fever. There has been no change in her usual antipar-
kinsonian treatment. On examination she was conscious but disori-
ented and with prominent visual hallucinations. Temperature was
41.2 8C. No meningeal signs were found. Severe generalized chor-
eatic dyskinetic movements were observed, more intense in the lower
limbs. Only a mild bilateral akinetic-rigid syndrome was detected.
The remainder of neurological and general examination was normal.
High plasma CK was found (up to 1455 IU/L). Blood, urine and cer-
ebrospinal fluid cultures, a cranial computerized tomography, and a
chest radiography showed no abnormalities.
Results: Treatment was started with intravenous fluids, antipyretic
measures and pramipexol was tapered and withdrawn within five
days. A small dose of quetiapine (25 mg/day) was added. Patient’s
clinical status progressively improved. Temperature and CK levels
normalized in few days and the severity of dyskinesias was greatly
reduced. Hallucinations remitted almost completely. Two months
later her neurological state remained unchanged.
Conclusions: We describe a patient with dyskinesia-hyperyrexia
syndrome, a severe complication of PD which, although shares some
of the features of the PHS, has some clinical differences (severe dys-
kinesias instead of rigidity) and a different therapeutic approach.
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Risk factors for freezing of gait in Parkinson’s disease
A. Contreras, F. Grandas (Madrid, Spain)
Objective: To determine possible risk factors for Freezing Of Gait
(FOG) in Parkinson’s disease.
Background: FOG is a major source of morbidity and poor qual-
ity of life in patients with Parkinson’s disease (PD). Although a com-
mon motor complication of PD, the risk factors for FOG are not well
understood.
Methods: Cross-sectional study involving 160 consecutive PD
patients. We screened patients for the presence of FOG and assessed
19 variables regarding clinical, neuroimaging and therapeutics
aspects, as well as gait and balance functional scales and timed tests.
A comparison between PD patients with and without FOG was per-
formed using statistical univariant analysis, followed by multivariant
logistic regression, Kaplan-Meier and ROC curves, and Cox models.
Results: 43,8% experienced FOG. Age of PD onset, disease dura-
tion, MMSE score, motor fluctuations, dyskinesias, UPDRS, Hoehn-
Yahr stating, Schawb-England score, balance and gait Tinetti Score,
falls and number and length of steps were significantly different
between patients with and without FOG. There were no differences
in antiparkisonian treatments and cerebrovascular disease. Hoehn-
S356 POSTER SESSION 2, TUESDAY, JUNE 15, 2010
Movement Disorders, Vol. 25, Suppl. 2, 2010
